The bradycardic agent zatebradine enhances baroreflex sensitivity and heart rate variability in rats early after myocardial infarction

Cardiovascular Research

Volumn 45, Issue 4, 2000, Pages 900-912

  Krüger, Carsten ^a   Landerer, Vera ^a   Zugck, Christian ^a   Ehmke, Heimo ^a   Kübler, Wolfgang ^a   Haass, Markus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autonomic nervous system; Baroreflex; Bradycardia; Heart rate (variability); Infarction

Indexed keywords

METHOXAMINE; NITROPRUSSIDE SODIUM; ZATEBRADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; CORONARY ARTERY LIGATION; DOSE RESPONSE; ELECTROCARDIOGRAM; HEART INFARCTION; HEART RATE VARIABILITY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; RAT; RR INTERVAL; VAGUS NERVE STIMULATION;

ANALYSIS OF VARIANCE; ANIMALS; BAROREFLEX; BENZAZEPINES; CARDIOTONIC AGENTS; HEART; HEART RATE; LINEAR MODELS; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC;

EID: 0343314914     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00405-8     Document Type: Article

References (49)

1. Kjekshus J., Gullestad L. Heart rate as a therapeutical target in heart failure. Eur Heart J. 1:(Suppl H):1999;H64-H69.
2. Schweizer M.W.F., Brachmann J., Kirchner U., et al. Heart rate variability in time and frequency domains: effects of gallopamil, nifedipine, and metoprolol compared with placebo. Br Heart J. 70:1993;252-258.
3. Kleiger R.E., Miller J.P., Bigger J.T. Jr., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 59:1987;256-262.
4. Lombardi F., Sandrone G., Pernpruner S., et al. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol. 60:1987;1239-1245.
5. Schwartz P.J., Zaza A., Pala M., et al. Baroreflex sensitivity and its evolution during the first year after myocardial infarction. J Am Coll Cardiol. 12:1988;629-636.
6. Osculati G., Grassi G., Giannattasio C., et al. Early alterations of the baroreceptor control of heart rate in patients with acute myocardial infarction. Circulation. 81:1990;939-948.
7. Farrell T.G., Odemuyiwa O., Bashir Y., et al. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J. 67:1992;129-137.
8. Hohnloser S.H., Klingenheben T., van de Loo A., et al. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. Circulation. 89:1994;1068-1073.
9. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 351:1998;478-484.
10. Ludwig A., Zong X., Jeglitsch M., Hofmann F., Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature. 393:1998;587-591.
11. Pape H.C. Specific bradycardic agents block the hyperpolarization-activated cation current in central neurons. Neuroscience. 59:1994;363-373.
12. Sawaki S., Furukawa Y., Inoue Y., Oguchi T., Chiba S. Zatebradine attenuates cyclic AMP-related positive chronotropic but not inotropic responses in isolated, perfused right atria of the dog. Clin Exp Pharmacol Physiol. 22:1995;29-34.
13. Glasser S.P., Michie D.D., Thadani U., Baiker W.M. Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine investigators. Am J Cardiol. 79:1997;1401-1405.
14. Bril A., Forest M.C., Cheval B., Landais L., Gout B. Effects of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits. Pharmacology. 48:1994;308-319.
15. Guth B.D., Heusch G., Seitelberger R., Ross J. Jr. Elimination of exercise-induced regional myocardial dysfunction by a bradycardic agent in dogs with chronic coronary artery stenosis. Circulation. 75:1987;661-669.
16. Aidonidis I., Brachmann J., Rizos I., et al. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. Cardiovasc Drugs Ther. 9:1995;555-563.
17. Furukawa Y., Xue Y.X., Chiba S., Hashimoto K. Effects of zatebradine on ouabain-, two-stage coronary artery ligation- and epinephrine-induced ventricular tachyarrhythmias. Eur J Pharmacol. 300:1996;203-210.
18. Coleman T.G. Arterial baroreflex control of heart rate in the conscious rat. Am J Physiol. 238:(Heart Circ Physiol 7):1980;H515-H520.
19. Billman G.E., Schwartz P.J., Stone H.L. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation. 66:1982;874-880.
20. Eckberg D.L., Sleight P. Human baroreflexes in health and disease. Boyd C.A.R., Brown A.G., Fink G., et al. Monogr Physiol Soc. 43:1992;78-95 Clarendon Press, Oxford, UK.
21. Akselrod S., Eliash S., Oz O., Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis. Am J Physiol. 253:(Heart Circ Physiol 22):1987;H176-H183.
22. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., et al. Myocardial infarct size and ventricular function in rats. Circ Res. 44:1979;503-512.
23. Deck C.C., Raya T.E., Gaballa M.A., Goldman S. Baroreflex control of heart rate in rats with heart failure after myocardial infarction: effects of captopril. J Pharmacol Exp Ther. 263:1992;1424-1431.
24. Teerlink J.R., Clozel J.P. Hemodynamic variability and circadian rhythm in rats with heart failure: role of locomotor activity. Am J Physiol. 264:(Heart Circ Physiol 33):1993;H2111-H2118.
25. DiBona G F., Sawin L.L. Reflex regulation of renal nerve activity in cardiac failure. Am J Physiol. 266:(Reg Integr Comp Physiol 35):1994;R27-R39.
26. Krüger C., Kalenka A., Haunstetter A., et al. Baroreflex sensitivity and heart rate variability in conscious rats with myocardial infarction. Am J Physiol. 273:(Heart Circ Physiol 42):1997;H2240-H2247.
27. Ytrehus K., Liu Y., Tsuchida A., et al. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol. 267:(Heart Circ Physiol 36):1994;H2383-H2390.
28. Seller H. Central baroreceptor pathways. Persson P.B., Kirchheim H.R. Baroreceptor reflexes. 1991;45-74 Springer-Verlag, Berlin.
29. Brown D.R., Brown L.V., Patwardhan A., Randall D.C. Sympathetic activity and blood pressure are tightly coupled at 0.4 Hz in conscious rats. Am J Physiol. 267:(Regul Integr Comp Physiol 36):1994;R1378-R1384.
30. Cerrutti C., Barrès C., Paultre C. Baroreflex modulation of blood pressure and heart rate variabilities in rats: assessment by spectral analysis. Am J Physiol. 266:(Heart Circ Physiol 35):1994;H1993-H2000.
31. Haass M., Dietz R., Fischer T.A., Lang R.E., Kübler W. Role of right and left atrial dimensions for release of atrial natriuretic peptide in left-sided valvular heart disease and idiopathic dilated cardiomyopathy. Am J Cardiol. 62:1988;764-770.
32. Da Prada M., Zürcher G. Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci. 19:1976;1161-1174.
33. Adamson P.B., Huang M.H., Vanoli E., et al. Unexpected interaction between β-adrenergic blockade and heart rate variability before and after myocardial infarction. Circulation. 90:1994;976-982.
34. Sakamoto M., Siri F.M., Solomon S.B., Tanimoto H., Yellin E.L. UL-FS 49 (zatebradine) does not affect arterial baroreflex in conscious normal or aortic-constricted rats. J Cardiovasc Pharmacol. 31:1998;488-492.
35. Kuwahara M., Yayou K.I., Ishii K., et al. Power spectral analysis of heart rate variability as a new method for assessing autonomic activity in the rat. J Electrocardiol. 27:1994;333-337.
36. Sleight P., La Rovere M.T., Mortara A., et al. Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of baroreflex gain? Clin Sci. 88:1995;103-109.
37. Karemaker J.M. Heart rate variability: why do spectral analysis? Heart. 77:1997;99-101.
38. Mangin L., Swynghedauw B., Benis A., et al. Relationships between heart rate and heart rate variability: study in conscious rats. J Cardiovasc Pharmacol. 32:1998;601-607.
39. Folkow B., DiBona G.F., Hjemdahl P., Toren P.H., Wallin B.G. Measurements of plasma norepinephrine concentrations in human primary hypertension. A word of caution on their applicability for assessing neurogenic contributions. Hypertension. 5:1983;399-403.
40. Sgoifo A., de Boer S.F., Westenbroek C., et al. Incidence of arrhythmias and heart rate variability in wild-type rats exposed to social stress. Am J Physiol. 273:(Heart Circ Physiol 42):1997;H1754-H1760.
41. Kageyama T., Nishikido N., Kobayashi T., et al. Long commuting time, extensive overtime, and sympathodominant state assessed in terms of short-term heart rate variability among male white-collar workers in the Tokyo megalopolis. Ind Health. 36:1998;209-217.
42. Chen J.S., Wang W., Bartholet T., Zucker I. Analysis of baroreflex control of heart rate in conscious dogs with pacing-induced heart failure. Circulation. 83:1991;260-267.
43. Umemura K., Zierhut W., Quast U., Hof R.P. Baroreflex and β-adrenoceptor function are diminished in rat cardiac hypertrophy due to volume overload. Basic Res Cardiol. 87:1992;263-271.
44. Khaykin Y., Dorian P., Tang A., et al. The effect of sinus node depression on heart rate variability in humans using zatebradine, a selective bradycardic agent. Can J Physiol Pharmacol. 76:1998;806-810.
45. Casadei B., Pipilis A., Sessa F., Conway J., Sleight P. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation. 88:1993;353-357.
46. Hull S.S., Vanoli E., Adamson P.B., et al. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation. 91:1995;2516-2519.
47. Vanoli E., De Ferrari G.M., Stramba-Badiale M., et al. Vagal stimulation and prevention of sudden cardiac death in conscious dogs with a healed myocardial infarction. Circ Res. 68:1991;1471-1481.
48. Thames M.D., Kinugawa T., Smith M.L., Dibner-Dunlap M.E. Abnormalities of baroreflex control in heart failure. J Am Coll Cardiol. 22:(Suppl A):1993;56A-60A.
49. Landolina M., Mantica M., Pessano P., et al. Impaired baroreflex sensitivity is correlated with hemodynamic deterioration of sustained ventricular tachycardia. J Am Coll Cardiol. 29:1997;568-575.